Breaking Down Northeast Pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors

Northeast Pharmaceutical Group's recent results demand a close look: revenue slid to CNY 6.134 billion in the first three quarters of 2024 (a -4.22% year-over-year drop) and a worrying -14.12% decline on a TTM basis to September 2025, driven by a -5.15% fall in preparations and an -11.84% drop in raw materials as all segments showed contraction; profitability is thin with a net profit margin of 3.59%, ROE at 6.65% and EPS of CNY 0.27, while the balance sheet shows conservative leverage-total debt of CNY 1.88 billion, a net cash position of CNY 1.95 billion and a debt-to-equity ratio of 33.26%-liquidity metrics include a current ratio of 1.09 and quick ratio of 0.91 with interest coverage of 6.79; valuation sits at a trailing P/E of 21.00, P/B of 1.53, EV/EBITDA of 7.00 and a market cap of CNY 8.08 billion, and the company faces regulatory, competitive and input-cost risks even as opportunities in R&D, emerging markets and strategic partnerships remain-read on for the full financial breakdown and what these figures mean for investors

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Revenue Analysis

• Reported revenue (1-3Q 2024): CNY 6.134 billion, down 4.22% year-on-year.
• Trailing twelve months (TTM) ending Sep 2025: revenue growth down 14.12% (TTM decline).
• Declines are broad-based across business segments, reflecting market pressures and rising competition.

• Preparation segment: revenue decrease of 5.15% - primary driver of overall underperformance.
• Raw material segment: revenue decrease of 11.84% - notable weakness in upstream products.
• Other revenue: decrease of 5.52% - indicates weakness beyond core segments.

• Market forces: increased competition and sector-wide challenges have pressured pricing and volumes.
• Investor considerations: revenue contraction magnitude (4.22% YoY for 1-3Q 2024; -14.12% TTM) warrants scrutiny of margin trends, product mix shifts and management actions to stabilize sales.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Profitability Metrics

• Net profit margin (1-3Q 2024): 3.59% - low absolute profitability for the period.
• Year-on-year net profit margin change (1-3Q 2024): -5.37% (decline vs. prior-year period).
• Return on equity (ROE, TTM ending Sep 2025): 6.65% - below typical industry benchmarks for pharmaceuticals.
• Earnings per share (EPS, TTM ending Sep 2025): CNY 0.27 - decreased relative to the prior TTM.
• Trend drivers noted: operational inefficiencies and increased cost pressures contributing to margin compression.

• Key implications for investors:
  • Lower net margin and falling EPS signal limited earnings power relative to peers.
  • Sub-7% ROE suggests returns on equity capital are modest and may lag industry returns.
  • Margin decline (-5.37% YoY) points to rising costs or pricing pressure; cost control and operational improvements are critical to reverse the trend.
• Areas to monitor going forward:
  • Gross margin and SG&A trends to identify where cost pressures are emerging.
  • R&D and product mix shifts that could affect long-term margin recovery.
  • Quarterly profitability updates and guidance from management for 2025-2026.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Debt vs. Equity Structure

• Net cash of CNY 1.95 billion vs. total debt of CNY 1.88 billion implies a net-delevered balance sheet (net cash position ≈ CNY 70 million).
• Debt-to-equity at 33.26% signals a more conservative stance than peers, reducing solvency risk during cyclical downturns.
• Interest coverage of 6.79 provides a comfortable margin to meet interest expenses, though not exceptionally high.

• Risk profile: Lower leverage reduces financial distress risk and supports creditworthiness; downside protection is stronger.
• Return trade-off: Conservative use of debt can limit financial return amplification (ROE uplift) during strong growth periods.
• Liquidity nuance: Current ratio (1.09) indicates working capital is adequate, but quick ratio (0.91) shows some reliance on inventories to meet short-term obligations.
• Capital allocation flexibility: Net cash position provides option value for M&A, buybacks, or R&D investment without immediate external financing.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Liquidity and Solvency

Northeast Pharmaceutical Group presents a liquidity profile that supports near-term obligations and a solvency posture that limits financial leverage. Key reported metrics include a current ratio of 1.09, a quick ratio of 0.91, a net cash position of CNY 1.95 billion, an interest coverage ratio of 6.79, and a debt-to-equity ratio of 33.26%.

• Current ratio 1.09 - sufficient short-term assets to cover short-term liabilities, though only marginally above 1.0.
• Quick ratio 0.91 - indicates reliance on inventory for liquidity; potential challenges if inventory is slow-moving.
• Net cash CNY 1.95 billion - provides a meaningful liquidity buffer and flexibility for working capital or investment.
• Interest coverage 6.79 - comfortably covers interest expenses, reducing default risk from operating shortfalls.
• Debt-to-equity 33.26% - conservative leverage, supporting solvency even under stress scenarios.

Investors should weigh the near-term liquidity tightness implied by a quick ratio below 1.0 against the offsetting strengths: a sizeable net cash balance and robust interest coverage. For fuller corporate context and background on strategic positioning, see Northeast Pharmaceutical Group Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Valuation Analysis

Northeast Pharmaceutical Group's current valuation metrics indicate a moderate market assessment relative to earnings, assets and cash-generation ability. Key headline figures provide a snapshot of how the market prices the company versus peers and historical norms.

• P/E = 21.00: Suggests investors expect steady earnings but not rapid near-term earnings acceleration; potential sensitivity to earnings misses.
• P/B = 1.53: Equity price includes a premium for intangibles, growth potential, or superior ROE versus pure asset liquidation value.
• EV/EBITDA = 7.00: Attractive versus many higher-growth pharma names; indicates reasonable pricing for cash-operating profitability.

Valuation drivers and investor considerations:

• Market cap (CNY 8.08bn) positions Northeast Pharmaceutical Group as a mid-sized player; liquidity and institutional coverage may be moderate.
• Metrics "in line with industry averages" reflect current investor sentiment that balances stable product revenue with regulatory and R&D risks.
• Expectations embedded in the multiples incorporate recent financial performance and projected growth - any deviation in reported earnings, margin expansion, or new product launches could re-rate the stock.

For further context on ownership and investor behavior that can influence valuation, see: Exploring Northeast Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Risk Factors

Northeast Pharmaceutical Group faces multiple risks that directly affect its financial health, cash flows and investor returns. Below are the principal risk categories with illustrative figures showing how these risks can interact with the company's operating and balance-sheet metrics.

• Regulatory approval and compliance risk: product pipeline delays or failed approvals can reduce near-term revenue recognition and inflate sunk R&D costs.
• Competitive pressure: domestic generics producers and multinational entrants can compress pricing and share, especially in key therapeutic areas.
• Raw material cost volatility: key API price swings affect gross margins and inventory revaluation.
• Currency exposure: export or imported-inputs create FX translation and transaction risk for reported RMB results.
• Healthcare policy & reimbursement changes: adjustments to national procurement, NRDL listings or reimbursement rates can materially affect demand and unit pricing.
• Legal and product liability: recalls, litigation or safety-related penalties can impose direct fines and indirect reputational damage reducing future sales.

Quantitative context (latest available annual / trailing figures used to illustrate sensitivity):

How each risk translates to financial line items and investor metrics:

• Regulatory delays -> deferred revenue and higher capitalized development costs; longer payback periods and lower IRR on pipeline projects.
• Competition -> lower ASPs (average selling prices), reduced market share, lower return on invested capital (ROIC).
• Raw-material inflation -> higher COGS, lower gross margin, squeezed operating margin and potential inventory write-downs.
• FX moves -> variance in reported revenue/COGS, potential translation losses affecting net income.
• Reimbursement shifts -> abrupt demand drops for affected drug lines, impairment testing triggers for goodwill/intangibles.
• Legal liabilities -> one-off charges, increased provisions, higher insurance and compliance spend going forward.

Practical stress scenarios (illustrative impacts on headline profit):

Risk mitigation levers management can deploy:

• Diversify supply chain and secure long-term API contracts to reduce input-price volatility.
• Accelerate higher-margin specialty and proprietary products to offset commoditized segments.
• Hedge material FX exposures and price internationally sourced inputs in RMB where possible.
• Increase compliance spend and post-market surveillance to lower product-liability probabilities.
• Maintain prudent liquidity buffer - target cash + undrawn facilities covering 6-12 months of operating cash needs.

For more on corporate direction and non-financial priorities that affect risk exposure, see: Mission Statement, Vision, & Core Values (2026) of Northeast Pharmaceutical Group Co., Ltd.

Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) - Growth Opportunities

• Expansion into emerging markets: targeting Southeast Asia, Africa and selected Latin American markets to diversify revenue and reduce domestic-concentration risk.
• Investment in research and development: increasing pipeline breadth for biologics, high-value generics and specialty therapies to capture higher-margin segments.
• Strategic partnerships and acquisitions: M&A or JV activity to acquire niche technologies, fill portfolio gaps and accelerate market entry.
• Adoption of digital technologies: process automation, digital supply-chain forecasting and CRM platforms to lower costs and boost commercial efficiency.
• Strengthening sales & distribution: expanding hospital access, community pharmacy penetration and e-commerce channels to increase unit volumes.
• Enhancing brand recognition: targeted medical education, KOL engagement and patient support programs to grow loyalty and prescribing share.

• Accelerate export approvals (CMC, registration) in prioritized emerging markets - potential incremental revenue of several hundred million RMB within 2-4 years if successful.
• Raise R&D intensity from ~3% to 5-7% of revenue over a 3-year horizon to develop 2-4 new mid-stage assets and multiple reformulated generics.
• Pursue bolt-on acquisitions in specialized segments (e.g., oncology supportive care, sterile injectables) to lift gross margin by capturing higher ASP products.
• Deploy digital sales tools and ERP upgrades to reduce working-capital days by 5-10 days, unlocking cash for reinvestment.
• Expand logistics hubs and cold-chain capabilities to increase hospital distribution reach by 15-25% in tier-2/3 cities.

• R&D spend as % of revenue (target: 5-7%).
• New product approvals / filings per year (target: 3-6).
• Export revenue share (target: increase from current single-digit % to 15-20% within 5 years).
• Gross margin expansion (target: +200-400 bps via premiumization & efficiency).
• ROIC and net-debt / EBITDA trends post-M&A or capex.